Results 101 to 110 of about 25,099 (263)

Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state

open access: yesAlzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The brain is a complex dynamical system, influenced by arousal state. Cortical synchrony supports information processing and is disrupted in Alzheimer's disease (AD). Locus coeruleus (LC) integrity and pupillometry index arousal system structure and function.
Michael C. B. David   +12 more
wiley   +1 more source

Switching cholinesterase inhibitors in patients with Alzheimer's disease

open access: yes, 2021
Despite recognition that cholinesterase inhibitors can provide clinical benefits for patients with Alzheimer's disease (AD), the average durations of treatment and beneficial effects are not optimal in all cases. This may be due to disappointing efficacy
Emre, M
core  

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a networkmeta-analysis (Protocol) [PDF]

open access: yes, 2019
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of each cholinesterase inhibitor in the treatment of adults with VCI. To compare cholinesterase inhibitors for efficacy
Shenkin, Susan D.   +5 more
core   +1 more source

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

open access: yesBrain and Behavior, Volume 16, Issue 6, June 2026.
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem   +5 more
wiley   +1 more source

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer’s Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16.106 Patients [PDF]

open access: yes, 2017
We investigated the effect of cholinesterase inhibitors on all-cause discontinuation, efficacy and safety, and the effects of study design-, intervention-, and patient-related covariates on the risk-benefit of cholinesterase inhibitors for Alzheimer’s ...
Barceló, Maria A.   +20 more
core   +1 more source

Monoamine Oxidase and Cholinesterase Inhibition Profiles of Semicarbazone and Thiosemicarbazone Derivatives

open access: yesChemistry &Biodiversity, Volume 23, Issue 6, June 2026.
Thiosemicarbazones generally show higher MAO‐B inhibitory potential than their corresponding semicarbazones, and particularly T6 is the most potent, which contains R = H and X = S in its Tail Unit, with an IC50 value of 6.45 µM with SI of 3.6. ABSTRACT Twenty semicarbazone and thiosemicarbazone derivatives (T1–T20) were synthesized and evaluated for ...
Sandeep Bindra   +11 more
wiley   +1 more source

Medications used in dementia: a review of evidence

open access: yesSri Lanka Journal of Psychiatry, 2015
Background Dementia is an acquired global impairment of intellect, memory and personality, without impairment of consciousness. It is usually progressive in nature. The management of dementia is mainly two faceted; pharmacological and non-pharmacological.
C. Suraweera, R. Hanwella, V.A. de Silva
doaj   +1 more source

Deciphering Antidiabetic, Anti‐Inflammatory, and Anti‐Cholinergic Bioactivities of Withania somnifera (L) Dunal Root Extract: An In Vitro and In Silico Investigation

open access: yesChemistry &Biodiversity, Volume 23, Issue 6, June 2026.
In this investigation, Withania somnifera root ethanol extract displays anti‐inflammatory and antidiabetic properties. Though compounds including withasomniferolide B and sitoindoside IX have been previously identified as phytoconstituents in the plant, in silico analysis from this study revealed them as new lead compounds that could act as potential ...
Lufuno Mulelu   +4 more
wiley   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng   +16 more
wiley   +1 more source

Trustwide Clinical Audit of Dementia Diagnosis: How Are Diagnoses Made and What Treatments Are Offered?

open access: yesBJPsych Open
Aims: To assess variations in dementia treatment, diagnosis, and pathway practices across the memory services in Tees, Esk and Wear Valleys (TEWV) NHS Foundation Trust and how these compare to Trust and national policy.
Olusegun Sodiya   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy